Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Schuttelaar, Marie-Louise A
von Berg, Andrea
Paller, Amy S
MetadataShow full item record
CitationPediatrics 2015, 135 (4):597-606
AbstractAtopic dermatitis (AD) primarily affects infants and young children. Although topical corticosteroids (TCSs) are often prescribed, noncorticosteroid treatments are needed because compliance with TCSs is poor due to concerns about their side effects. In this longest and largest intervention study ever conducted in infants with mild-to-moderate AD, pimecrolimus 1% cream (PIM) was compared with TCSs.
A total of 2418 infants were enrolled in this 5-year open-label study. Infants were randomized to PIM (n = 1205; with short-term TCSs for disease flares) or TCSs (n = 1213). The primary objective was to compare safety; the secondary objective was to document PIM's long-term efficacy. Treatment success was defined as an Investigator's Global Assessment score of 0 (clear) or 1 (almost clear).
Both PIM and TCSs had a rapid onset of action with >50% of patients achieving treatment success by week 3. After 5 years, >85% and 95% of patients in each group achieved overall and facial treatment success, respectively. The PIM group required substantially fewer steroid days than the TCS group (7 vs 178). The profile and frequency of adverse events was similar in the 2 groups; in both groups, there was no evidence for impairment of humoral or cellular immunity.
Long-term management of mild-to-moderate AD in infants with PIM or TCSs was safe without any effect on the immune system. PIM was steroid-sparing. The data suggest PIM had similar efficacy to TCS and support the use of PIM as a first-line treatment of mild-to-moderate AD in infants and children.
DescriptionTo access publisher's full text version of this article click on the hyperlink at the bottom of the page
RightsArchived with thanks to Pediatrics
- A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal.
- Authors: Weidinger S, Baurecht H, Schmitt J
- Issue date: 2017 Oct
- Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
- Authors: Wahn U, Bos JD, Goodfield M, Caputo R, Papp K, Manjra A, Dobozy A, Paul C, Molloy S, Hultsch T, Graeber M, Cherill R, de Prost Y, Flare Reduction in Eczema with Elidel (Children) Multicenter Investigator Study Group.
- Issue date: 2002 Jul
- The treatment of facial atopic dermatitis in children who are intolerant of, or dependent on, topical corticosteroids: a randomized, controlled clinical trial.
- Authors: Hoeger PH, Lee KH, Jautova J, Wohlrab J, Guettner A, Mizutani G, Hultsch T
- Issue date: 2009 Feb
- A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids.
- Authors: Murrell DF, Calvieri S, Ortonne JP, Ho VC, Weise-Riccardi S, Barbier N, Paul CF
- Issue date: 2007 Nov
- Effectiveness and safety of a prevention-of-flare-progression strategy with pimecrolimus cream 1% in the management of paediatric atopic dermatitis.
- Authors: Sigurgeirsson B, Ho V, Ferrándiz C, Andriano K, Grinienko A, Jimenez P, Pimecrolimus 1% cream in (paediatric) Eczema: Prevention of Progression multi-centre investigator study group.
- Issue date: 2008 Nov